Table S1.
Baseline characteristics of enrolled studies
| Study | Year | Treatment | Number of patients evaluated for toxicity | Number of patients experienced toxicity (grade ≥3)/all grade
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hand-foot syndrome | Weight loss | Diarrhea | Rash | Mucositis | Hypocalcemia | Hyper tension | Nausea | Fatigue | Anorexia | Voice change | Vomiting | Increased ALT | Increasing AST | ||||
|
| |||||||||||||||||
| Schneider et al1 | 2012 | Sorafenib | 31 | 7/22 | 3/18 | 2/16 | 5/17 | 3/16 | 0/15 | 5/15 | 0/3 | NA | NA | NA | NA | NA | NA |
| Brose et al2 | 2014 | Sorafenib | 207 | 42/158 | 0/97 | 12/142 | 10/104 | 2/48 | 19/39 | 20/84 | 0/43 | 12/103 | 5/66 | 1/25 | 1/23 | 6/26 | 2/23 |
| Cabanillas et al3 | 2015 | Lenvatinib | 58 | NA | 7/40 | 6/39 | NA | 1/18 | NA | 6/44 | 0/29 | 5/35 | 1/30 | 0/25 | 0/22 | NA | NA |
| Schlumberger et al4 | 2015 | Lenvatinib | 261 | 9/83 | 25/121 | 21/155 | 1/42 | 11/93 | 7/18 | 109/177 | 6/107 | 24/154 | 12/131 | 3/63 | 5/74 | 0/1 | 0/1 |
| Berdelou et al5 | 2017 | Lenvatinib | 75 | 0/21 | 0/44 | 1/34 | NA | 2/18 | NA | 26/50 | 0/14 | 6/46 | 1/27 | 0/1 | 0/5 | NA | NA |
| Nervo et al6 | 2018 | Lenvatinib | 12 | 2/11 | 2/11 | 5/8 | NA | 1/7 | NA | 5/9 | 1/9 | 1/7 | NA | 0/3 | 1/4 | NA | NA |
| Balmelli et al7 | 2018 | Lenvatinib | 13 | 0/1 | NA | 2/4 | NA | 1/4 | NA | 1/2 | NA | 2/6 | 1/3 | 0/1 | NA | NA | NA |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not available.